Urological Cancer Kieran Jefferson Consultant Urological Surgeon
Urological Cancer
-
Upload
meducationdotnet -
Category
Documents
-
view
226 -
download
1
Transcript of Urological Cancer
![Page 1: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/1.jpg)
Urological Cancer
![Page 2: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/2.jpg)
BLADDER CANCER
• 2nd commonest urological malignancy
• 3.5% of all cancers worldwide
• M:F = 2:1
• Incidence increases with age
![Page 3: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/3.jpg)
AETIOLOGY
• Smoking
• Occupational
• Chronic infection
• Drugs
• Genetic/Familial
![Page 4: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/4.jpg)
HISTOPATHOLOGY
• Transitional Cell
• Squamous Cell
• Adenocarcinoma
![Page 5: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/5.jpg)
HISTOPATHOLOGY
• Field Change
• Grade 1-3
• Stage Ta – T4
N0-N1
M0-M1
![Page 6: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/6.jpg)
PRESENTATION
• Haematuria
• Infection
• Mass
![Page 7: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/7.jpg)
INVESTIGATION
• Cystoscopy
• CT
• MRI
![Page 8: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/8.jpg)
![Page 9: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/9.jpg)
TREATMENT
• SUPERFICIAL – Transurethral Resection – Intravesical Chemo/Immunotherapy
• INVASIVE – Radical Surgery – Radiotherapy – Systemic Chemotherapy
Superficial >80% 5-year survival
Invasive 25-50% 5-year survival
![Page 10: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/10.jpg)
![Page 11: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/11.jpg)
PROSTATE CANCER
• Commonest male cancer (33%)
• Increasing incidence younger males
• Case fatality rate 20%
![Page 12: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/12.jpg)
AETIOLOGY
• Testosterone
• Race
• Family History
• Diet
• Smoking
![Page 13: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/13.jpg)
HISTOPATHOLOGY
• Peripheral zone
• Local spread
– Perineural
– seminal vesicle
• Metastatic spread
– regional lymph nodes
– bones, lungs, viscera
Seminal Vesicle
![Page 14: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/14.jpg)
HISTOPATHOLOGY
• Adenocarcinoma
• Prostatic Intraepithelial Neoplasia
• Grade: Gleason Score 2-10
• Stage T1-4, N0-1, M0-1
![Page 15: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/15.jpg)
PRESENTATION
ASYMPTOMATIC
• Raised Prostate Specific Antigen
• Abnormal Digital Rectal Examination
![Page 16: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/16.jpg)
PRESENTATION
LOCAL SYMPTOMS
• Haematuria
• Haematospermia
• Bladder Outlet Obstruction
![Page 17: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/17.jpg)
PRESENTATION
ADVANCED SYMPTOMS
• Lymphoedema
• Pathological Fracture
• Spinal Cord Compression
• Anaemia
• Ureteric Obstruction
![Page 18: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/18.jpg)
INVESTIGATION
• PSA
• Transrectal Ultrasound Biopsy
• Isotope Bone Scan
• CT
• MRI
![Page 19: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/19.jpg)
Staging Prostate Cancer
![Page 20: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/20.jpg)
T1 T2
T3 T4
N1
M1
![Page 21: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/21.jpg)
Gleason Grade
![Page 22: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/22.jpg)
Gleason Score • Gleason grading
• Sum of Dominant and sub-dominant histology
+ = 7 3 4
![Page 23: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/23.jpg)
![Page 24: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/24.jpg)
![Page 25: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/25.jpg)
TREATMENT
CONSERVATIVE
• Watchful Waiting
• Active Surveillance
![Page 26: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/26.jpg)
TREATMENT
CURATIVE
• Radical Prostatectomy
• Radiotherapy
![Page 27: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/27.jpg)
• Open prostatectomy
Radical Prostatectomy
![Page 28: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/28.jpg)
• Laproscopic prostatectomy
Radical Prostatectomy
![Page 29: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/29.jpg)
• Robotic prostatectomy
Radical Prostatectomy
![Page 30: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/30.jpg)
• Robotic prostatectomy
– Enhanced magnification, scaling and movement
– Reduced blood loss
– Reduced post operative pain
– Faster recovery
Radical Prostatectomy
![Page 31: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/31.jpg)
Prostate Cancer Radiotherapy
• Target identification – Tumour
– Prostate
– Seminal Vesicles
• Organs at risk – Rectum
– Bladder
– Penile Bulb
![Page 32: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/32.jpg)
![Page 33: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/33.jpg)
![Page 34: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/34.jpg)
![Page 35: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/35.jpg)
![Page 36: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/36.jpg)
TREATMENT
ADVANCED DISEASE
Endocrine Therapy
Chemotherapy
• Corticosteroids
• Palliation
![Page 37: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/37.jpg)
![Page 38: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/38.jpg)
![Page 39: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/39.jpg)
PROGNOSIS
• Early
Most live > 10y
• Metastatic
Few survive 5y
![Page 40: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/40.jpg)
RENAL CANCER
• 2% of all cancers
• >200 new cases annually in NI
• M:F = 2:1
• Highest incidence >75 y/o
![Page 41: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/41.jpg)
AETIOLOGY
• Inherited
Von Hippel-Lindau Syndrome
Hereditary Papillary Renal Cell Carcinoma Syndrome
• Smoking
• Obesity
• Polycystic renal disease
![Page 42: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/42.jpg)
HISTOPATHOLOGY
• Solid/Cystic
• Clear cell 75%
• Papillary 10%
• Chromophobe 10%
• Oncocytoma
• Collecting duct tumours Glomerulus
Tubule
Clear Cell Tumour
![Page 43: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/43.jpg)
PRESENTATION
• 40% Incidental
• Haematuria
• Mass
• Pain
![Page 44: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/44.jpg)
PRESENTATION
LATE
• Paraneoplastic phenomena
• Metastatic
• Varicocoele
![Page 45: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/45.jpg)
INVESTIGATION
• Ultrasound
• CT
• MRI
• Angiography
TNM STAGING
![Page 46: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/46.jpg)
![Page 47: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/47.jpg)
TREATMENT
Organ-Confined
• Radical Nephrectomy
• Nephron Sparing Surgery
![Page 48: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/48.jpg)
TREATMENT
Metastatic
• Palliative irradiation/surgery/embolisation
• Immunotherapy
• Growth factor receptor inhibitors
![Page 49: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/49.jpg)
PROGNOSIS
• T1-2 N0 M0 80% 5 year survival
• Metastatic disease 10% 5 year survival
![Page 50: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/50.jpg)
TESTICULAR CANCER
• Commonest cancer males age 15–34
• 85% 20–50 y/o
• 1-2% all male cancers
![Page 51: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/51.jpg)
RISK FACTORS
• Cryptorchidism
• Previous History
• Family History
![Page 52: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/52.jpg)
HISTOPATHOLOGY
95% Germ Cell
Seminoma
Teratoma (Non Seminoma)
Lymphoma
Sertoli
Leydig Cell
Metastases
![Page 53: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/53.jpg)
PRESENTATION
• Most present early
• Painless mass
• Hydrocoele
• Undescended – inguinal or pelvic mass
• Metastases
![Page 54: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/54.jpg)
INVESTIGATION
• Tumour Markers – a-FetoProtein
– b-Human Chorionic Gonadotrophin
– Lactate Dehydrogenase
• Pathology
![Page 55: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/55.jpg)
INVESTIGATION
Imaging
• Ultrasound
• CT
• MRI
![Page 56: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/56.jpg)
TREATMENT
• Radical Orchidectomy
• Adjuvant Therapy
– Seminoma
• Radiotherapy
• Chemotherapy
– Non Seminomatous Germ Cell Tumour (Teratoma)
• Combination Chemotherapy
• Retroperitoneal Lymph Node Dissection
![Page 57: Urological Cancer](https://reader031.fdocuments.us/reader031/viewer/2022030222/58842bb01a28ab485c8b7751/html5/thumbnails/57.jpg)
PROGNOSIS
98% >10 year survival
Treatment Risks
• Carcinogenesis
• Pulmonary fibrosis
• Peripheral neuropathy